The Anatomy of a 1000% Markup: When life-saving medicine becomes corporate profit

In late September 2026, the Supreme Court of India voiced what millions of families battling catastrophic illness have known for decades. Hearing a series of petitions on medicine pricing under the Drugs (Prices Control) Order (DPCO), a bench of Justices Vikram Nath and Sandeep Mehta delivered a scathing assessment of hospital drug pricing practices. 

Observing a cancer formulation supplied to retailers for ₹2,700 being sold to patients at a Maximum Retail Price (MRP) of ₹27,000, the bench described the 1,000 per cent markup in blunt terms: "This is carnage. Plain and simple."

The court’s observation cuts directly to the heart of a structural crisis within the pharmaceutical supply chain. How did life-saving oncology treatments — and everyday essential medicines — become commercial instruments generating multi-fold profit margins at the hospital counter?

The Economics of In-House Pharmacies and Trade Margins

To understand how a ₹2,700 drug reaches a patient at ₹27,000, one must look closely at trade margin structures and institutional purchasing mechanics. In the Indian pharmaceutical distribution framework, the Price to Retailer (PTR) reflects the rate at which manufacturers sell drugs to hospital pharmacies and stockists.

Under current DPCO rules, scheduled formulations (essential medicines appearing on the National List of Essential Medicines) have capped retail prices and capped trade margins — typically restricted to 16 per cent for retailers. However, non-scheduled formulations, which constitute roughly 80 per cent of the market by number and value, give manufacturers and institutions wide latitude in setting the printed MRP.

This disparity creates a perverse financial incentive:

Procurement Bidding: Corporate hospitals often request manufacturers to print a high MRP on non-scheduled drugs while negotiating steep institutional discounts on the PTR.

Captive Patient Base: Hospitals frequently enforce strict internal policies requiring admitted patients to buy drugs exclusively from in-house pharmacies.

The Supreme Court noted that this practice deprives patients of competitive market discounts and shifts an undue burden onto both families and public tax-funded insurance schemes.

High MRP vs. Low Production Cost: Fact-Based Industry Benchmarks

The gap between manufacturing cost, procurement price, and printed MRP is not unique to a single oncology formulation. Regulatory studies by the National Pharmaceutical Pricing Authority (NPPA) and market analyses have repeatedly highlighted significant price distortions across non-scheduled formulations and medical consumables.

The following table provides examples of drug categories where the gap between the Price to Stockist /Retailer (or production cost) and the printed Maximum Retail Price has historically reached extreme levels prior to or outside strict price controls:

Regulatory Loopholes and the Challenge of Combination Drugs

A major factor enabling high retail prices is the regulatory distinction between scheduled single-ingredient medicines and fixed-dose combinations (FDCs).

As the Supreme Court observed during the hearing, a standalone generic statin may carry a regulated, modest ceiling price. However, when combined into a single pill with aspirin or another agent, the resulting combination formulation frequently exits the scheduled price-cap list. This allows manufacturers and distributors to set significantly higher retail prices.

Furthermore, under current framework rules, non-scheduled drugs are permitted an automatic annual price escalation of up to 10 per cent. Over a five-to-ten-year cycle, this compound allowance widens the baseline discrepancy between physical production costs and final consumer costs.

Towards Trade Margin Rationalisation (TMR)

The Supreme Court’s query — asking why a uniform 16 per cent margin cannot be applied across all formulations — points toward a systemic policy solution: Trade Margin Rationalisation (TMR).

Capping the Spread: TMR caps the maximum percentage spread between the price at which a manufacturer sells to the trade (PTR) and the final price paid by the patient (MRP). When the NPPA previously applied a 30 per cent trade margin cap on selected non-scheduled anti-cancer drugs, MRPs dropped by 50 to 85 per cent across hundreds of brands, saving patients hundreds of crores annually.

Ending Captive Pharmacy Monopolies: Ensuring patients in private and corporate hospitals have the freedom to buy prescribed medications from external licensed pharmacies or generic outlets fosters open market competition.

Harmonising FDC Pricing: Closing the gap between single-molecule ceiling prices and multi-drug combinations prevents formulations from circumventing price controls.

Restoring Balance to Healthcare Delivery

Pharmaceutical manufacturing requires sustainable returns to fund research, development, and quality compliance. However, when the distribution chain transforms life-saving therapies into high-markup commodities, the core objective of healthcare is compromised.

By addressing inflated trade margins and institutional sales practices, regulatory authorities have an opportunity to ensure that scientific advances in medicine remain genuinely accessible to the patients who need them most.


#DrugPricing #PharmaTruths #AffordableHealthcare #SupremeCourtIndia #HealthcareReforms #NPPA #DPCO #CancerAwareness #PatientRights #HealthcareForAll